
Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday. First approved to treat obesity by the U.S. Food and Drug Administration last November, Zepbound’s power was significant: It reduced sleep apnea severity by nearly… read on > read on >